Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy

Comparison of clinical and immunological effects of intravenous and intradermal administration of {alpha}-GalactosylCeramide (KRN7000) - pulsed dendritic cells

Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine

Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection

Adjuvant activity mediated by iNKT cells

Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer

REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress

Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial

A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer

Invariant natural killer T cell-based immunotherapy for cancer

REGiMMUNE Presented Enhanced Efficacy Data in Preclinical Transplantation Models at the 2009 American Transplant Congress

A Phase I Study of Alpha-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

KRN7000 in Treating Patients With Solid Tumors- lung cancer

KRN7000 in Chronic Hepatitis B

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection

Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in
highly coordinated secondary activation of acquired and innate immunity

A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer

Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer

Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors

Population pharmacokinetics of the novel anticancer agent KRN7000

Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells

 

 

New 7DW8-5 glycolipid

7DW8-5

Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

 

Meet Funakoshi Company
at the following meetings:

AACR
Washington DC
April 1-5, 2017

The 11th Annual Meeting of Japanese Society for Epigentics
Tokyo, Japan
May 22-23, 2017

The 36th Annual Meeting of Japanese Association of Forensic Toxicology

The 21st Annual Meeting of Japanese Assocation of Cancer Immunology
Chiba, Japan
June 28-30, 2017

The Japanese Society for Genome Editing
Osaka, Japan
June 28-30, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

NIH Festival
Bethesda, Maryland
September 2017

ASCB
Philadelphia, PA
December 2-6, 2017